HDAC3-dependent transcriptional repression of FOXA2 regulates FTO/m6A/MYC signaling to contribute to the development of gastric cancer
Zhi Yang, Xiaodi Jiang, Zhenghou Zhang, Zitian Zhao, Weijia Xing, Yiwei Liu, Xiaofeng Jiang & Haiying Zhao

In the current study, we aim to elucidate whether histone deacetylase 3 (HDAC3) exerts oncogenic role in GC, and investigate the possible mechanism.

Cancer Gene Ther. 2020 Jul 13.  

Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report
DAPENG DONG, GE SHEN, YONG DA, MING ZHOU, GANG YANG, MINGMING YUAN, RONGRONG CHEN

"This study suggested that crizotinib was an offthe-shelf, practical, and ostensibly effective treatment option for patients with ovarian cancer with ROS1 rearrangement. NGS-based genetic testing may guide to plan therapeutic paradigms, and render precision medicine promising in ovarian cancer treatment."

Oncologist. 2020 Jul 11.  

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
Caicun Zhou, Xingya Li, Qiming Wang, Guanghui Gao, Yiping Zhang, Jianhua Chen, Yongqian Shu, Yanping Hu, Yun Fan, Jian Fang, Gongyan Chen, Jun Zhao, Jianxing He, Fengying Wu, Jianjun Zou, Xiaoyu Zhu, Xiang Lin

Pyrotinib showed promising antitumor activity and an acceptable safety profile in chemotherapytreated patients with HER2-mutant NSCLC.

J Clin Oncol. 2020 Jul 2;JCO2000297. 

Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features
"Qiufang Liu, Dazhen Sun, Nan Li, Jinman Kim, Dagan Feng, Gang Huang, Lisheng Wang, Shaoli Song"

In our study, we established predictive models based on radiomic analysis of 18F-FDG PET/CT images. And it achieved a satisfying prediction power in the identification of EGFR mutation status as well as the certain EGFR mutation subtypes in lung cancer.

Transl Lung Cancer Res. 2020 Jun; 9(3): 549–562.

Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma
Weiquan Gu, Na Wang, Weiguang Gu, Yuan Qiu, Hua Zhang, Jianmiao Liang, Tongfei Zhou, Liheng Ma, Weijing Cai, Weineng Feng, and Likun Chen

Variations in the incidence of mutations in signaling pathways involved in lung adenocarcinoma and the correlation of the signaling pathways with TMB may exist across different ethnic groups.

Transl Lung Cancer Res. 2020 Jun; 9(3): 629–638.

Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versusHER2-directed therapies
Jiebai Zhou, Ning Ding, Xiaobo Xu, Yong Zhang, Maosong Ye, Chun Li and Jie Hu

"Pemetrexed-based chemotherapy remains an important component of care for patients with HER2-mutant NSCLC. HER2-TKI given as an initial therapy may bring more clinical benefits than when given as a subsequent-line therapy. Refining the patient population based on patterns of HER2 variants may help improve the efficacy of anti-HER2 treatment in lung cancer. Developing highly effective and tolerable HER2-targeted agents is urgently needed for this population."

Ther Adv Med Oncol. 2020 Jun 27;12:1758835920936090.

am8亚美下载